Polarean Imaging PLC Phase III Clinical Trials - Update (7478B)
11 Junio 2019 - 1:01AM
UK Regulatory
TIDMPOLX
RNS Number : 7478B
Polarean Imaging PLC
11 June 2019
Polarean Imaging Plc
("Polarean" or the "Company")
Phase III Clinical Trials - Update
Polarean Imaging plc (AIM: POLX), the clinical stage
medical-imaging technology company, with a proprietary drug-device
combination product for the visualisation of pulmonary function in
the magnetic resonance imaging (MRI) market, announces a further
update regarding the Company's Phase III Clinical Trials (the
"Clinical Trials"), following the Company's announcement of 13 May
2019.
Clinical Trials
The Clinical Trials continue to progress at Duke University and
at the University of Virginia and aim to demonstrate
non-inferiority of the Company's drug-device combination, which
uses hyperpolarised 129-Xenon gas MRI, against an approved
comparator for the evaluation of pulmonary ventilation.
Enrolment for the Clinical Trials has now passed 85.4% in the
lung transplant pathway and 62.5% the lung resection pathway.
To improve the rate of enrolment for the lung resection pathway,
the Company will now add a third trial site at the University of
Cincinnati ("UC"), which is already one of the Company's key
clinical collaborators. It is expected that the first patient will
be enrolled at UC shortly.
With the addition of the UC trial site, completion of enrolment
for the Clinical Trials will now extend into Q32019.
Polarean's Directors remain confident that the Company is on
track to meet its current timetable for the regulatory submission
of a New Drug Application with the US Food and Drug Administration
(FDA). If approved by the FDA, commercial launch is expected to
occur during H22020.
Richard Hullihen, CEO of Polarean, said: "We are pleased to
confirm that Polarean will be activating the additional trial site
at UC this month, to help ensure a timely completion of the
enrolment process for the lung resection pathway.
Enrolment for the lung transplant pathway is now nearing
completion and I look forward to providing shareholders with
further updates regarding our Clinical Trials as soon as
practicable."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
David Hignell / Lindsay Mair / Jamie Spotswood
(Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44
(0)7879 741 001
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESFBLLFKQFLBBE
(END) Dow Jones Newswires
June 11, 2019 02:01 ET (06:01 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024